Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Novartis logo

Novartis

Status and phase

Completed
Phase 3

Conditions

Osteoporosis

Treatments

Drug: Zoledronic Acid
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00145327
CZOL446H2301E1

Details and patient eligibility

About

This extension study is designed to assess the long term safety and efficacy of zoledronic acid in postmenopausal women with osteoporosis who have participated in the CZOL446H2301 (NCT00049829): HORIZON Pivotal Fracture Trial. This extension study began after the 3-year core study ended. Baseline is the same as Year 3.

Enrollment

2,456 patients

Sex

Female

Ages

68 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who have received 3 infusions in the HORIZON-Pivotal Fracture (PFT) Study.

Exclusion criteria

  • Poor kidney, eye, or liver health
  • Use of certain therapies for osteoporosis in the HORIZON-PFT study (other than the study medication)
  • Abnormal calcium levels in the blood

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

2,456 participants in 3 patient groups, including a placebo group

Zoledronic Acid 6
Experimental group
Description:
Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
Treatment:
Drug: Zoledronic Acid
Zoledronic Acid 3 Placebo 3
Placebo Comparator group
Description:
Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
Treatment:
Drug: Placebo
Placebo 3 Zoledronic Acid 3
Experimental group
Description:
Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
Treatment:
Drug: Zoledronic Acid

Trial contacts and locations

31

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems